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Background:  Cholinergic  components  in  non-neuronal  tissues  and  cells  are proposed  as  important  in
maintaining  cellular  proliferation  and  immune  homeostasis.  However,  direct  quantiﬁcation  of  non-
neuronal  acetylcholine  (ACh)  in  cells has  been  inefﬁcient.  Therefore,  we  developed  a  stable  method  for
determination  of intracellular  ACh.
Methods:  We  used  ultra  performance  liquid  chromatography-tandem  mass  spectrometry  (UPLC–MS/MS)
with Waters  CORTECS  chromatographic  columns  to measure  the  intracellular  ACh in  human  peripheral
blood  mononuclear  cells  (PBMCs).  The  presence  of  ACh  was validated  by RT-qPCR  of mRNAs  of  cholinergic
components.
Results:  This  method  successfully  separated  ACh  from  iso-ACh  with  highly  sensitive  precursor/product
ion  transitions  and  allowed  a faster  chromatography  run time  within  3.5 min.  The detection  limit  of
intracellular  ACh  was 0.005  ng/106 PBMCs.  Intra-assay  and  inter-assay  coefﬁcient  variations  were  all
<7.0%.  Mean  recoveries  in  the  samples  were  between  93.20%  and  104.73%.  Here,  intracellular  ACh  was
stable under  multiple  storage  conditions,  partly  attributable  to mutually  stable  relationships  among
cholinergic  components.  This  method  was successfully  applied  in  a  stroke  study  and  revealed  activation
of  the  stroke-induced  cholinergic  anti-inﬂammatory  pathway.
Conclusions:  This  method  allows  direct  determination  of  intracellular  ACh  in  various  tissues.  Evidences
of  cholinergic  activity  linking  both  the  nervous  system  and  non-neuronal  system  can  be proﬁled  by
ublis
assessing  ACh.
©  2016  The  Authors.  P
. Introduction
Acetylcholine (ACh) is a classical cholinergic neurotransmitter
f crucial electrical activity in the nervous system. Nevertheless,
ccumulating evidence suggests that ACh is also synthesized by a
iversity of non-neuronal tissues [1], such as those bearing immune
ells and epithelial cells [2–5]. The participation of non-neuronal
Ch is indispensible for cell proliferation, gland secretion and
mmune regulation [6,7]. However, few studies have established
 valid and stable method for objectively quantifying ACh in these
ells.
In early investigations, radiochemical assays were used for iden-
ifying ACh in blood and plasma. However, such radiologic assays,
∗ Corresponding author.
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/).hed  by  Elsevier  B.V.  This  is  an  open  access  article  under the  CC  BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
which were indirect and radiological, lacked sufﬁcient speciﬁcity
[8]. Further, it is still debatable whether ACh is actually present
in human plasma, because ACh degrading enzymes are so abun-
dant that considerable effort is required to detect even traces of
ACh. Chromatography has also been applied for this purpose, i.e.,
gas chromatography-mass spectrometry, high performance liquid
chromatography with electrochemical detection and high per-
formance liquid chromatography with mass spectrometry. These
methods are commonly used in micro-dialysates of animal brain
but are laborious, time consuming, or inadequate because of low
limits of detection, insufﬁcient separation sensitivity and requi-
site usage of derivatization [9–15]. The difﬁculty is instability
of ACh under conditions of enzymatic and chemical degrada-
tion in the cerebral spinal ﬂuid. The property hampered delicate
sample preparation that may  require speciﬁc precautions, includ-
ing an indirect method of electrochemical detection. Recently,
the enzyme-linked immune-sorbent assay (ELISA) provided an
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.
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Fig. 1. ACh and iso-ACh have similar chemical structures and hydrophilic natures. (A) ACh can be degraded by AChE into choline and acetyl-CoA. (B) Iso-ACh is hydroxylated
by  BBOX into l-carnitine, the last step in the l-carnitine biosynthesis pathway.
Table 1
Instrument parameters for UPLC–MS/MS analysis of ACh, iso-ACh and D9-ACh.
Analyte Parent ions (m/z) Product ion (m/z) Cone voltage (V) Collision energy (eV) Retention time (min)
ACh 146.10 60.01 20.00 10.00 1.91
146.10  86.98 20.00 13.00
iso-
ACh
146.10  60.01 20.00 10.00 2.19
146.10  86.98 20.00 13.00
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ltrasensitive method for measuring the release of ACh by using
cetylcholinesterase (AChE, EC 3.1.1.7) for the conversion of ACh
o choline(Fig. 1A) [16]. But as is known, choline is not only the
recursor of ACh formed by choline O-acetyltransferase (ChAT, EC
.1.3.6) but is almost always present in various cells for the synthe-
is of phospholipids. Therefore, the ELISA method may  not exclude
he interference of endogenous choline present in cells and body
uids [17].
Another urgent problem to be solved in detecting ACh is its
ifferentiation from the natural isomer of ACh (iso-ACh), butyro-
etaine (BB, (3-carboxypropyl)trimethylammonium) (Fig. 1B). This
ntrinsic precursor of carnitine has the same molecular weight as
ut minor structural differences from ACh. In cell metabolism, iso-
Ch is an essential material in the transport of activated long-chain
atty acids from the cytosol to the mitochondrial matrix. So the
ossible interference of iso-ACh should not be overlooked while
ttempting to determine ACh content in cells [18,19].
Here, a rapid and selective ultra performance liquid
hromatography-tandem mass spectrometry (UPLC–MS/MS)
ethod was developed and validated for the simultaneous
uantiﬁcation of ACh and iso-ACh in human peripheral blood
ononuclear cells (PBMCs). Compared to a previous study of
Ch in liver tissue [18], our method provided a much shorter
ime for analysis and freedom from endogenous matrix inter-
erence with an isotope internal standard. The efﬁciency was
bviously improved for preparing batch samples. Subsequently,
e successfully applied this method to a clinical study of stroke
atients.
. Materials and methods
.1. Chemicals and reagents
Acetylcholine chloride was purchased from Sigma-Aldrich (St.
ouis, MO,  USA). The internal standard acetylcholine-D9 chlo-
ide was from C/D/N (Quebec, Canada). The butyrobetaine was
urchased from TCI (Tokyo, Japan). Physostigmine salicylate was
rom Sigma-Aldrich. The 99% ammonium formate, 98% formic acid
LC–MS grade, Sigma-Aldrich, St Louis. Mo,  USA) and acetonitrile.00 13.00 1.91
.00 10.00
were obtained from Merck Chemicals (HPLC grade, Merck KGaA,
Darmstadt, Germany).
2.2. Liquid chromatographic conditions
The analysis was performed using a Waters Acquity ultra-
performance liquid chromatography (Waters Corporation, Milford,
MA, USA) consisting of a binary pump, an automatic sampler and a
column compartment. The analytes were separated on the Waters
Acquity CORTECS hydrophilic interaction liquid chromatography
(HILIC) column (100 mm × 2.1 mm;  1.6 m).The column tempera-
ture was set to 40 ◦C. The ﬂow rate was 0.4 mL/min. The solvents
were 50 mmol/L ammonium formate (solvent A, pH adjusted to
3 with formic acid) and acetonitrile (solvent B) with a gradient
over the 3.5 min  run time as follows: 20% A (initial), 20–50% A
(0–0.75 min),50–70% A (0.75–1.25 min), 70–70% A (1.25–1.7 min),
70–20% A (1.7–2.1 min),20–20% A (2.1–3.5 min). All gradient steps
were linear. The sample injection volume was  5 L.
2.3. Mass spectrometric conditions
Identiﬁcation and quantiﬁcation of the target analytes and their
internal standard were performed by a triple quadrupole mass
spectrometer (Xevo-TQ-S mass spectrometer, Waters Corporation,
Milford, MA,  USA) using a positive electrospray ionization (ESI)
mode. The source temperature was  150 ◦C, capillary voltage was
0.40 kV, desolvation gas (N2) temperature was  350 ◦C at a ﬂow rate
of 700 L/h, and the cone gas (N2) ﬂow rate was 50 L/h. Collision gas
(Ar) ﬂow was maintained at 0.30 L/h. Individual cone and collision
energy voltages, as well as multiple reaction monitoring (MRM)
mass transitions are summarized in Table 1.
2.4. Preparation of standards
Stock solutions of acetylcholine chloride (50 mg/50 mL)  and
acetylcholine-D9 chloride (50 mg/50 mL)  were prepared in
acetonitrile-water (50:50 v/v) and stored in a refrigerator at 4 ◦C.
Standard solutions were prepared by diluting the ACh stock solu-
tion with acetonitrile-water (50:50 v/v). Each calibration standard
atogr. 
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sed for the analysis of the samples was prepared by pipette
ixing 10 mL  of each ACh standard solution with 10 mL of the
nternal standard solution in a pulled point glass vial insert to give
 series of standards with ACh concentrations of 0.05, 0.1, 0.2, 0.5,
.0, 2.0, 3.0, 5.0 ng/mL, iso-ACh concentrations of 0.5, 1.0, 2.0, 3.0,
.0 ng/mL. Terminal concentrations of D9-ACh concentrations for
easurements of intracellular ACh and iso-ACh were, respectively,
 ng/mL and10 ng/mL.
.5. Sample sources and preparation
Before clinical use, we tested UPLC–MS/MS conditions repeat-
dly in 25 healthy volunteers (mean age 50 years). For comparison
f intracellular ACh levels in ischemic stroke, PBMCs were isolated
rom four groups: 50 healthy individuals, 46 patients with chronic
troke, 19 patients with transient ischemic stroke (TIA) and 102
atients with acute ischemic stroke. Demographic characteristics
f the 4 groups are listed in Supplementary Table 1. EDTA-blood
as obtained by standard veni-puncture techniques. PBMCs were
ollected by centrifugation with Histopaque 1077(Sigma-Aldrich)
ccording to the manufacturer’s instructions, followed by counting
ith a Countess® automated cell counter (Invitrogen, Life Tech-
ologies, CA, USA). Freshly isolated PBMCs were added to 100 L
eionized H2O/0.1% formic acid (vol:vol), and vortexed for 15 s to
ake into homogenates. The homogenates were further broken
ltrasonically and deproteined by adding 300 L acetonitrile con-
aining internal standard. The sample was vortexed again for 1 min
hen centrifuged at 15000 rpm for 10 min  [20]. The supernatant was
ltered through 0.22 m organic membranes and transferred to an
utosampler glass vial.
.6. Assay and quality control
Assays were validated for speciﬁcity, linearity, accuracy, pre-
ision, recovery and stability according to the FDA guidelines on
io-analytical method validation. Validation runs were conducted
n three consecutive days. Calibration standards were analyzed
efore the samples within each analysis batch. Assay linearity of
he calibration curve was evaluated with calibration standard solu-
ions. The lower limit of detection (LOD) for the measurement of
Ch and iso-ACh in samples was determined by analyzing a series
f decreasing concentrations of standard solution until the signal
f each compound was three times greater than baseline noise
S/N = 3). Here, instrument sensitivity was evaluated by LOD con-
idering the respective matrix effects and the loss of the analytes
uring sample preparation.
Intra-assay variation was assessed by analyzing quality con-
rol (QC) samples in six replicates at three concentration levels
low, medium and high) on a single day. Inter-assay variation was
lso evaluated using the same three levels of QC samples at con-
entrations on three consecutive validation days. The intra-assay
ariation and inter-assay variation were assessed by analyzing QC
amples with spiked biological matrix.
Precision and accuracy of the method were determined by
nalyzing the QC samples at four concentrations (n = 5 at each con-
entration level) on three separate days. Accuracy was calculated
y comparing the mean experimental concentrations of assayed
C samples with their nominal values, and percentage values were
sed as the index. Relative standard deviation (RSD) of the concen-
rations was used as an index of precision. In addition, a separate
ystems suitability test was done just before analyzing each set
f samples by performing six replicate injections of a calibration
tandard. RSDs of peak areas and retention times were calculated,
nd acceptance criteria were set at 15% and 2%, respectively. We
ssessed the linear range and sensitivity of the assay by adding
.01–400 ng/mL ACh or iso-ACh to the PBMCs. The peak-area ratiosB 1022 (2016) 265–273 267
of acetylcholine or iso-ACh to D9-ACh were determined and plot-
ted against the concentrations of ACh and iso-ACh. The assay was
routinely calibrated by analyzing four samples containing added
ACh (3, 7.5, 15, and 30 ng/mL) and iso-ACh (0.6, 1.5, 3, and 6 ng/mL)
in freshly isolated PBMCs. To determine intra-batch precision, we
used data from the recovery experiments. The inter-batch preci-
sion was determined by assaying the same samples on 20 different
days over a period of 3 weeks.
Analyte stability was  evaluated in several samples from the
same individual. The room temperature and 4 ◦C storage stability of
ACh in human PBMCs were evaluated in triplicate using QC samples.
Their stability in the autosampler was assessed by re-injecting an
entire run. The processed sample stability was assessed by testing
processed and stored QC samples against freshly prepared stan-
dards. The cell samples were incubated at 4 ◦C or 25 ◦C for up to
10 h. The incubation times were 2 h, 4 h, 6 h and 10 h. Each sample
was run in triplicate. Selectivity of the method and the instrument
performance during extended use were assured by performing a
sequence of 100 injections of standard solutions spiked with ACh.
To evaluate the effects of AChE inhibitors on the measurement of
ACh, we  added increasing concentrations of physostigmine sali-
cylate (10 M,  100 M,  1 mM and 10 mM)  to the vacuette blood
collection tubes.
2.7. Cholinergic activity measurement
AChE catalytic activity was measured by referring to Ofek’s
method [21].Total RNA was  extracted from human PBMCs, which
served as a positive control, using the QIAGEN RNeasy mini kit
(QIAGEN, Hilden, Germany). RNA concentration and quality were
assessed based on 260 nm/280 nm absorbance ratios. 1 g of total
RNA was used to synthesize the ﬁrst-strand cDNA, as described
in SuperScript III Platinum Two-Step qRT-PCR Kit (Invitrogen, Life
Technologies, CA, USA). 2 L of the cDNA obtained was ampliﬁed in
a 25 L reaction system containing 25 pmol of the respective for-
ward and reverse primers and AmpliTaq DNA polymerase (Takara,
Dalian, China). The PCR ampliﬁcation protocols for cholinergic
components entailed 35 cycles of denaturation at 95 ◦C for 30 s,
annealing at 58 ◦C for 30 s and extension at 72 ◦C for 30 s to 1 min.
ACTB (-actin) mRNA was  used as an internal control for the efﬁ-
ciency of cDNA ampliﬁcation. Primers used for quantitative RT-PCR
were from Invitrogen, Life Technologies (Supplementary Table 2).
All reactions were run in triplicate. In addition, no-reverse tran-
scriptase controls were run with all RNAs to check for genomic
DNA contamination.
3. Results and discussion
3.1. Method development and optimization
The present method was designed to obtain sufﬁcient retention
of the analytes to provide satisfactory separation from various inor-
ganic salts eluting at the solvent front and endogenous compounds.
We began by comparing three representative columns (ZORBAX
SB-Aq, Acquity BEH C18, Acquity CORTECS) on the basis of the peak
shape and retention times. First, we  examined the hydrophilic ZOR-
BAX SB-Aq, a fused-core particle technology column that provided a
symmetric peak shape and retention characteristics. However, like
many traditional C18HPLC columns, this column failed to isolate
ACh from iso-ACh or other unknown materials present in lym-
phocytes. Next, the AcquityTM UPLC BEH HILIC column separated
ACh from iso-ACh, but achieved a broad peak shape with a lower
through put (12 min  run time). Subsequently, the CORTECS column
yielded a faster analysis (3.5 min  run time) and acceptable peak
shape symmetry. The CORTECS column also achieved a greater res-
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Fig. 2. Representative UPLC–MS/MS multiple reaction monitoring chromatograms
of  ACh, iso-ACh and D9-ACh synthesized by PBMCs. Stable isotope D9-labeled ACh
(parent ion m/z, 154.99) internal standard coeluted with PBMC- extracted ACh (par-
e
(
w
o
(
r
t
(
p
(
e
u
a
a
a
w
t
r
a
t
m
p
m
a
b
(
t
o
a
t
d
r
m
l
t
Ant ion m/z, 146.1) and was observed at an LC retention time of 1.91 min  Iso-ACh
parent ion m/z, 146.1) eluted at an LC retention time of 2.19 min. All chromatograms
ere acquired after injecting 1 ng/mL of ACh, iso-ACh and D9-ACh on-column.
lution (R = 2.1) of ACh and iso-ACh than the BEH HILIC column
R = 1.4). Effective separation of ACh from iso-ACh followed with
etention times at 1.91 min  and 2.19 min, respectively. Total run
ime was 3.5 min, which ensured the high-throughput of the assay
Fig. 2).
Both ACh and iso-ACh are water soluble chemicals with strong
olarity. It is difﬁcult for reversed-phase liquid chromatography
RPLC) columns to separate them, as shown in our experiment. Oth-
rwise, in HILIC column, a wide range of polar stationary phases are
sed with an aqueous-organic mobile phase. HILIC retention mech-
nisms are a complex combination of partitioning, ion-exchange
nd hydrogen bonding, resulting in enhanced retention for polar
nalytes. In HILIC, a polar stationary phase, used in combination
ith a high organic mobile phase results in retention of analytes
hat are simply too polar to be retained by RPLC. Also the organic-
ich mobile phase causes a reduction of the column back-pressure
nd efﬁcient desolvation of the electrospray-ionization mass spec-
rometry. RPLC employs a non-polar stationary phase and a polar
obile phase. As a result, non-polar molecules in the polar mobile
hase tend to adsorb to the non-polar stationary phase, and polar
olecules in the mobile phase will pass through the column and
re eluted ﬁrst, non-polar molecules can be eluted from the column
y decreasing the polarity of the mobile phase using an organic
non-polar) solvent, which reduces hydrophobic interactions. So
heir numerous applications include the analyses and separations
f many very polar or even ionizable (HILIC) and of neutral, moder-
tely polar or strongly hydrophobic (RPLC) compounds. In addition
o the enhanced retention of polar compounds, HILIC has several
istinct advantages over RPLC. These include the volatility of ACN-
ich mobile phases (ease of coupling and better sensitivity with
ass spectrometry) and low operating pressures to achieve a giveninear velocity, offering the potential for two-dimensional separa-
ions [22].
By monitoring the transitions, a robust and sensitive assay for
Ch was developed. A stable isotope-labeled analogue of ACh, D9-B 1022 (2016) 265–273
ACh, with high isotopic purity was selected as the internal standard,
to ensure uniform behavior of the analyte and also the internal stan-
dard in the entire analytical instrumentation. No cross-talk was
observed between MS/MS  channels used for monitoring ACh, iso-
ACh and the internal standard, nor were any problems noted with
isotopic integrity of the label during the sample processing. A divert
valve was  used to prevent inorganic salts in the samples from enter-
ing the source. The column eluate diverted to the ion source was
set at 0.2 min  in the gradient procedure (total time 0–3.5 min).
Good ACh and iso-ACh ion intensity and lower levels of back-
ground noise could be achieved with ESI source. By using ESI with
a mobile phase containing 50 mmol/L ammonium formate (solvent
A, formic acid adjust pH to 3), which was absolutely necessary
to achieve sufﬁcient chromatographic retention of ACh, the sen-
sitivity was improved. Inclusion of gradient of acetonitrile in the
mobile phase increased the ACh ionization further without detri-
ment to the chromatography. With ESI, the molecular ions for ACh
and the internal standard, D9-ACh, were found to be m/z  146.1 and
154.99, respectively. In previous studies, the structure of the prod-
uct ion of ACh was proposed as either a cation (m/z 87.04) or a
radical (m/z 87.10) that included the quaternary ammonium moi-
ety of the precursor ion. The accurate mass measurements using
quadrupole time-of-ﬂight (Q-TOF) supported that the product ion
was the cation. In this study, both the ACh and iso-ACh produced
identical product ions (m/z 86.98), offering further evidence that
the product ion was, indeed, acation. Overall, the protonated molec-
ular [M + H]+ ions for ACh (m/z 146.1), iso-ACh (m/z 146.1), D9-ACh
(m/z 154.99) were the predominant Q1 ions obtained by ESI in
the positive-ion mode by infusion of the respective compounds.
Under relatively mild collision-activated dissociation conditions,
each compound broke down to give essentially two major frag-
ments (m/z 86.98, 60.01 for ACh and iso-ACh, m/z 87.14, 69.03 for
D9-ACh).
The present work demonstrated minimal matrix effect on mea-
surement of the analytes. Improved chromatography to separate
interfering compounds from analytes was obtained. We  set up slow
gradient elution that helped to wash the column after injection
and prevented late-eluting compounds from the previous injec-
tion to interfere. Considering that ACh and iso-ACh are ionizable,
the pH of the mobile phase can have a signiﬁcant impact on reten-
tion, selectivity and sensitivity of the separation. We then adjusted
the pH of the mobile phase to reduce detriments to matrix effects.
The CORTECS column combines the polar bonded stationary phases
and mobile phases with a high content of organic solvents and
provides a complementary separation and thus greater freedom
from matrix effects compared to RPLC. MS  sensitivity can also
be improved by using the higher content of organic solvent in
the mobile phase. UPLC increases the speed and resolution of the
method by incorporating a CORTECS column and high pressures,
both of which improve separation from endogenous compounds
and reduce matrix effects.
3.2. Calibration curve linearity and sensitivity
Assay linearity was  evaluated using 5 calibration standard solu-
tions over the nominal concentration range of 0.05 ng/mL and
5 ng/mL for ACh, 0.5 ng/mL and 5 ng/mL for iso-ACh. The calibra-
tion curve equation was  y = bx + c, where y represented the analyte
to internal standard peak area ratio and x represented the concen-
tration of the standard solutions. The calibration curve was linear
over the concentration range investigated. Concentrations of these
standard solutions correlated strongly with the peak areas. That
is, the mean equation of the calibration curves (n = 6) shown in
parentheses was ACh (y = 2.2521x + 0.0038, r2 = 0.9993) and iso-
ACh (y = 1.0037x + 0.4152, r2 = 0.9995) (Fig. 3A, B). The coefﬁcients
of linear regression for two  independent experiments were both
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Fig. 3. ACh was  stably present in PBMCs. (A) and (B) Representative ACh and iso-ACh standard curves are shown. For each standard the m/z 146/155 ratio (ACh or iso-
ACh/D9-ACh internal standard) was calculated. The x axis of the standard curve represents the concentration range of the analyte (ACh and iso-ACh) standards, and the y
axis  represents the “instrument response value,” shown as peak area ratio of the ACh or iso-ACh standard relative to their D9-ACh stable isotope–labeled internal standard.
(C)  ACh and iso-ACh secreted by human PBMCs were kept separately at 4 ◦C or 25 ◦C (room temperature) for up to 10 h. Both ACh and iso-ACh remained essentially stable
under  all circumstances tested (P > 0.05). (D)Quantitative analysis of ACh secreted by human PBMCs in the absence of physostigmine salicylate (0 M)  and in the presence
of  different concentrations of physostigmine salicylate for 30 min: 10 M,100 M,  1 mM,  10 mM.  No signiﬁcant difference was found among the subgroups (P > 0.05), which
indicated that intracellular ACh was independent of acetylcholinesterase (AChE) or its inhibitor.
Table 2
Lower detection limits (LOD) and recovery of UPLC–MS/MS method for the analysis of ACh and iso-ACh.
Analyte LOD (ng/106 cells) Recovery
Intrinsic (ng/106 cells, mean ± SD) Added (ng) Measured (ng/106 cells, mean ± SD) Recovery (SD)(%)
ACh 0.005 0.08 ± 0.02 0.06 0.15 ± 0.02 93.93
0.24 0.33 ± 0.06 94.6
0.48 0.55 ± 0.08 95.38
0.12 0.55 ± 0.03 104.73
0.48 0.91 ± 0.11 93.2
0.96 1.40 ± 0.15 95.5
r
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Table 3
Precision and accuracy of UPLC–MS/MS method for the analysis of ACh and iso-Ach.
ACh iso-ACh
LQC MQ  HQ LQC MQ  HQ
Intra-batch
Mean (ng/106) cells) 0.05 0.15 0.45 0.2 0.4 0.8
SD  0.01 0.02 0.04 0.02 0.07 0.11
%CV  6.2 2.9 2.1 4.6 4.6 3.9
Inter-batch
Mean (ng/106) cells) 0.05 0.14 0.43 0.18 0.39 0.78
SD  0.01 0.03 0.07 0.03 0.09 0.14
%CV  7.1 3.7 4.2 5.3 3.9 4.6
Notes: LQC, low quality control; MQC, medium quality control; HQC, high qualityiso-ACh 0.003 0.44 ± 0.14 
2 > 0.999, and therefore the equations were selected for curve ﬁt-
ing. The lower limits of detection, deﬁned, as a signal-to-noise
S/N) of 3, were 0.005 ng/106 cells for ACh and 0.003 ng/106 cells
or iso-ACh, respectively (Table 2), which was superior to those in
 previous study [20].
.3. Precision and recovery
The precision and recovery of the assay were investigated at
ow- to high-normal concentrations of ACh and iso-ACh, as well as
n quality control samples at deﬁned concentrations. Mean ana-
ytical recoveries in the samples were 94.6% for ACh and 97.8%
or iso-ACh. The intra-batch imprecisions, that is, the coefﬁcients
f variation (CVs), expressed as %Dev, were 2.1–6.2% for ACh and
.9–4.6% for iso-ACh. The inter-batch CVs were 3.7–7.1% for ACh
nd 3.9–5.3% for iso-ACh (Table 3). The highest CVs for ACh prob-
bly related to the low concentrations of the analytes. The resultscontrol; SD, standard deviation; %CV, percent coefﬁcient of variation. n = 20 for all
measurements.demonstrated that the method was accurate and precise for the
analysis of ACh and iso-ACh.
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.4. Stability of PBMC-derived ACh and cholinergic components
xpression
The room temperature and 4 ◦C storage stability of ACh in
uman PBMCs were evaluated in triplicate using QC samples.
he stability of processed samples was assessed by testing pro-
essed and stored QC samples against freshly prepared standards.
ince the plasma and cytoplasm contains a large amount of
holinesterase (AChE), internal standard or standard ACh was
dded only after PBMCs were made into homogenates with formic
cid in case internal standard or ACh may  be quickly degraded
y AChE in plasma and cytoplasm. This acid environment should
nhibit AChE activity sufﬁciently. To establish the stability of the
nalytes, the deviations of the mean measured concentrations of
he test samples must be within ±15% of the nominal concentra-
ions. In our hands, we found that, samples incubated at 25 ◦C or 4 ◦C
or up to 10 h underwent no signiﬁcant degradation of the analytes
t any time point (P > 0.05) (Fig. 3C).
To ensure the stability of the analyte during human blood sam-
le collection and processing, the stability of ACh in PBMCs was
lso evaluated by pre-adding different concentrations of physostig-
ine to the peripheral blood sample. Although physostigmine may
nter the cells and inhibit AChE in the cytoplasm, we found that
dequate inhibition of AChE did not change intracellular ACh con-
ent (P > 0.05) (Fig. 3D), which meant that intracellular ACh was
ndependent on physostigmine or plasma AChE.
The stock solution stability of ACh, iso-ACh and their inter-
al standard in acetonitrile was also evaluated at both ambient
emperatures and at 4 ◦C as part of the validation. Results for
he determination of stock solution stability were calculated by
omparing mean response ratios (area of response per unit of con-
entration) of stability solutions to mean response ratios of freshly
repared control solutions. To establish the stock solution stability
f the analytes, the means of the responses of the two solutions
ust be within 5.0% of each other. ACh stock solutions were deter-
ined to be stable for at least 24 h at room temperature for 120 days
t 4 ◦C.
Since we detected intracellular ACh in PBMCs, we proposed
hat the immune cells involved might possess a cholinergic sys-
em that could synthesize, store and degrade ACh much as neurons
o. Real-time PCR was then performed to characterize choliner-
ic gene expression in healthy volunteers. Signiﬁcant expression of
holine O-acetyltransferase (ChAT) mRNA, vesicular acetylcholine
ransporter (VAChT) mRNA and AChE mRNA was detected in rat
rain, which served as a positive control. Correspondently, we
onﬁrmed that human PBMCs did express the cholinergic com-
onents. We  investigated relationships between the components
f the cholinergic system. More interestingly, we  found a strong
ositive correlation of ChAT mRNA levels with VAChT mRNA lev-
ls (Spearman r = 0.44, P = 0.04) and AChE mRNA levels (Spearman
 = 0.49, P = 0.03). Although the AChE mRNA levels also correlated
ith VAChT mRNA levels (Spearman r = 0.68, P < 0.01) (Fig. 4A–C),
o such correlations were noted between plasma AChE activity and
ntracellular AChE activity (Spearman r = 0.12, P = 0.535) in volun-
eers (Fig. 4D).
Kawashima detected and measured ACh concentrations in
uman plasma as about 0.4 ng/mL [8]. However, with our more
ensitive UPLC–MS/MS detection method, we found that human
lasma lacks ACh, regardless of our addition of adequate AChE
nhibitor or not (data not shown). One possible reason is that ACh
s maintained only in stable acidic environments, especially when
he pH value is between 3 and 4.5, whereas the pH of human
lasma is normally 7.35–7.45. Others found that ACh rapidly dis-
ppeared in vitro with a half life of 1.9 ± 0.4 min  in either fresh
at cerebrospinal ﬂuid without physostigmineor pre-incubated
ith the enzyme for as short a time as 6 min  [23]. This outcomeB 1022 (2016) 265–273
indicated that cerebrospinal ﬂuid ACh is dependent on AChE activ-
ity. Previously, cholinesterases inhibitors, such as neostigmine,
physostigmine, or organophosphate compounds were required to
detect ACh in biological ﬂuids. However, of particular note, we
found that intracellular ACh is relatively stable and not dependent
on cholinesterase inhibitors. No inhibitory effects of physostigmine
were observed in the present work. This paradox indicates that
the cholinergic system manifests signiﬁcantly different patterns of
distribution in body ﬂuids versus intracellular components.
However, strikingly, in our study, intracellular ACh was stable
for up to 10 h at room temperature or 4 ◦C even when kept in cells
without physostigmine. We  further found a mutual relationship
between ChAT, AChE and VAChT mRNA quantitative expression,
similar to that in pancreatic alpha cells [24]. This mutuality reﬂects
the close afﬁliation of these cholinergic components related to
maintenance of intracellular ACh balance. Others have conﬁrmed
the presence of ChAT, AChE and VAChT proteins during intracellular
reactivity in peripheral lymphocytes [25]. Further, VAChT immune
reactivity in vesicle-like structures might suggest that lympho-
cytes share with neurons the same ACh storage system that ensures
intracellular ACh independence of AChE degradation [26]. We  spec-
ulated that the existence of VAChT in cells is responsible for keeping
the intracellular ACh stable. A possible explanation for why intra-
cellular ACh is not dependent on AChE comes from reports that
ACh may  be stored in ACh transporter vesicles located in differ-
ent compartments from AChE in the cytoplasm. In this context, an
important factor is the convenient method we  have developed for
detecting ACh in multiple cell types with no need to consider AChE
degradation. The stabilities of ACh and iso-ACh in stock solution
and in the ﬁnal extract were also evaluated. When prepared in the
stock solution at a concentration of 1 mg/mL, the neat standards
of all analytes remained stable for up to 10 h at room tempera-
ture and for at least 1 month at 4 ◦C. Nonspeciﬁc binding caused
by adherence to glass surfaces was  not observed for ACh under the
conditions tested.
Overall, compared with a previous work reported by Wang
et al. [18], our new method with Waters CORTECS HILIC column
provided a much shorter time of total separation time (3.5 min
vs 17.0 min), which ensured the high-throughput of the assay.
Our method shortens the overall time of detection and obviously
improves efﬁciency for batch samples. Subsequently, we found
that intracellular ACh in PBMCs is not dependent on cholinesterase
inhibitors. Instead, this ACh content may result from the presence
of VAChT which could store endogenous ACh. Besides, the lower
limit of detection and the linear range both exceed that of Wang’s
method, ensuring detection of much lower concentrations of ACh
in cells under these experimental conditions. Our isotope inter-
nal standard dilution technique not only improved recovery rate
of analysis, but also monitored real-time ionization efﬁciency of
mass spectrum system, which increased accuracy and stability.
The higher concentration of buffer solution (50.0 mM)  effectively
improved peak width and achieved better separation of ACh from
iso-ACh.
3.5. Application in clinical studies
We  applied the stable quantiﬁcation system in ischemic stroke.
Importantly, total ACh content in PBMCs tended to increase in
patients with ischemic stroke compared to controls. But only the
subgroup with acute ischemic stroke had signiﬁcantly greater
amounts of total ACh in PBMCs (control: 0.19 ± 0.03 ng; chronic
ischemic stroke: 0.20 ± 0.02 ng; TIA: 0.22 ± 0.04 ng; acute ischemic
stroke: 0.32 ± 0.02 ng; P < 0.01).Post-hoc analysis revealed that
ACh concentrations reached the level of statistical signiﬁcance in
acute ischemic stroke patients compared with controls (P = 0.016)
(Fig. 5A). Further, when comparing ACh concentrations per PBMC,
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Fig. 4. Mutual relationships existed among ACh-associated cholinergic components. (A–C) Simple correlations between choline O-acetyl transferase (ChAT), vesicular acetyl-
choline transporter (VAChT) and acetylcholinesterase (AChE) mRNA relative expression were found in PBMCs from 15 healthy blood donors. (D) No signiﬁcant association
was  found between intracellular AChE catalytic activity and plasma AChE activity. Levels of expression are relative to the amount of ACTB.
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concentrations per PBMC with National Institute of Health strokeig. 5. Peripheral ACh was  associated with stroke severity. Comparison of PBMC-de
P < 0.05.(C, D) showed relationships between intracellular ACh and National Institu
he results were similar (control: 0.08 ± 0.01 ng/106 cells; chronic
schemic stroke: 0.13 ± 0.02 ng/106cells; TIA: 0.12 ± 0.03 ng/106
ells; acute ischemic stroke: 0.16 ± 0.01 ng/106 cells; P = 0.011; con-
rols versus acute ischemic stroke: P < 0.01) (Fig. 5B).Ch contents expressed by total PBMCs (A) and per 106 PBMCs (B). Error bars = SEM.
ealth stroke scale (NIHSS) or high-sensitivity C-reactive protein (hsCRP) level.
Moreover, a signiﬁcant correlation was found for individual AChscale (NIHSS) values (Spearman r = 0.31, P = 0.02) (Fig. 5C). Amounts
of the inﬂammation marker, high-sensitivity C-reactive protein
were also elevated signiﬁcantly in patients with acute ischemic
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troke (Supplementary Table 1, P = 0.03). Additionally, a positive
orrelation was present between individual ACh concentrations per
BMC cell and high-sensitivity C-reactive protein levels (Spearman
 = 0.34, P = 0.01) (Fig. 5D).
Our method proved to be successful in studies of human
schemic stroke and importantly, found an association between
BMC-derived ACh and acute ischemic stroke, thereby, provid-
ng direct evidence of an activated cholinergic pathway [21,27,28].
s has been suggested, lymphocyte cholinergic markers may
eﬂect the status of homologous brain systems. In this regard, a
elationship between cognitive impairment and changes in the
xpression of lymphocyte cholinergic receptors was  reported in
geing patients, those with Alzheimer’s disease and individuals
ith other neurodegenerative disorders [29–31].
. Conclusions
We  have developed a stable UPLC–MS/MS method to quan-
ify intracellular ACh and iso-ACh in human PBMCs. As a result,
) ACh and iso-ACh were seperated from each other by using
ORTEX columns in UPLC–MS/MS, which was superior to reversed-
hase, ion exchange or ion-pair chromatography; ii) human
BMCs were established as possessing the cholinergic systems
equired for the synthesis, storage and degradation of ACh; iii)
he potential involvement of PBMC-derived cholinergic system in
troke-induced inﬂammation was predicted for the ﬁrst time. Simi-
arly, we believe that peripheral lymphocyte-derived ACh might act
s a cholinergic marker of numerous cholinergic-related diseases,
or example, Parkinson’s disease and myasthenia gravis.
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